Published in Sci Rep on July 31, 2017
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol (2003) 84.79
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Rfam: annotating non-coding RNAs in complete genomes. Nucleic Acids Res (2005) 25.49
TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res (2006) 22.20
WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics (2008) 18.58
NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res (2005) 17.61
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
UniProt: a hub for protein information. Nucleic Acids Res (2014) 16.72
Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet (2006) 8.23
Diagnosis and classification of diabetes mellitus. Diabetes Care (2006) 7.91
Gene regulation by riboswitches. Nat Rev Mol Cell Biol (2004) 7.00
Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One (2010) 6.61
RNAMotif, an RNA secondary structure definition and search algorithm. Nucleic Acids Res (2001) 4.96
Liver and adipose expression associated SNPs are enriched for association to type 2 diabetes. PLoS Genet (2010) 3.75
ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res (2006) 3.60
Type 2 diabetes: new genes, new understanding. Trends Genet (2008) 3.35
Diabetes mellitus and the β cell: the last ten years. Cell (2012) 3.31
ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev (2005) 2.76
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
RegRNA: an integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res (2006) 2.43
Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes (2002) 2.32
Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia (2001) 2.25
Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature (2013) 2.19
UTRdb and UTRsite (RELEASE 2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res (2009) 2.11
Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes (2011) 2.03
Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet (1998) 2.02
Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol (2012) 1.99
Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.98
fRNAdb: a platform for mining/annotating functional RNA candidates from non-coding RNA sequences. Nucleic Acids Res (2006) 1.94
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford) (2015) 1.71
Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res (1990) 1.65
MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One (2011) 1.60
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia (2001) 1.53
Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Hum Genet (2013) 1.48
Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians. Diabetologia (2005) 1.47
The genetic architecture of type 2 diabetes. Nature (2016) 1.43
Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis (2008) 1.43
Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes (2001) 1.42
Vitamin A increases nerve growth factor and retinoic acid receptor beta and improves diabetic neuropathy in rats. Transl Res (2014) 1.41
Medicine. Environmental biology and human disease. Science (2007) 1.39
SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol (2007) 1.38
Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care (2013) 1.34
ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther (2011) 1.32
Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol (2007) 1.31
Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci (2008) 1.29
Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care (2004) 1.28
Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.25
Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet (2014) 1.25
Genome-wide association studies and type 2 diabetes. Brief Funct Genomics (2011) 1.24
Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia (2012) 1.23
Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract (2008) 1.21
Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes. PLoS Comput Biol (2010) 1.18
Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol Nutr Food Res (2015) 1.18
Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) (2015) 1.16
miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes (2012) 1.16
Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res (2010) 1.13
Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin Exp Immunol (2007) 1.12
Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes (2001) 1.10
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PLoS One (2009) 1.09
Low plasma leptin levels contribute to diabetic hyperphagia in rats. Diabetes (1999) 1.08
Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis (2010) 1.07
MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One (2013) 1.04
Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia (2007) 1.03
Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience (2011) 1.03
Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care (2005) 1.02
Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol (2010) 1.02
High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis (2010) 1.00
Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun (1998) 1.00
T2D-Db: an integrated platform to study the molecular basis of Type 2 diabetes. BMC Genomics (2008) 0.98
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One (2014) 0.97
Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. Metabolism (2014) 0.96
Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS One (2014) 0.95
Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp Clin Endocrinol Diabetes (2013) 0.95
Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS One (2011) 0.95
Moderate GLUT4 overexpression improves insulin sensitivity and fasting triglyceridemia in high-fat diet-fed transgenic mice. Diabetes (2013) 0.95
Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J (2015) 0.94
Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrol Dial Transplant (2012) 0.94
TCF7L2 variation and proliferative diabetic retinopathy. Diabetes (2013) 0.93
A meta-analysis of receptor for advanced glycation end products gene: four well-evaluated polymorphisms with diabetes mellitus. Mol Cell Endocrinol (2012) 0.93
High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia (2006) 0.93
Lipid level and type alter stearoyl CoA desaturase mRNA abundance differently in mice with distinct susceptibilities to diet-influenced diseases. J Nutr (1997) 0.92
Type 2 diabetes genetic association database manually curated for the study design and odds ratio. BMC Med Inform Decis Mak (2010) 0.92
Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics (2011) 0.92
Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol (2010) 0.91
MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol (2014) 0.90
Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology (2013) 0.90
TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (2008) 0.90
MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes (2012) 0.89
Identification of miR-106b-93 as a negative regulator of brown adipocyte differentiation. Biochem Biophys Res Commun (2013) 0.89
MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. Mol Cell Endocrinol (2013) 0.89
The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. Hum Mol Genet (2014) 0.89
Elevated plasma retinol-binding protein 4 is associated with increased risk of type 2 diabetes in middle-aged and elderly Chinese adults. J Nutr (2014) 0.89
Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab (2014) 0.89
Genome-wide association studies (GWAS): impact on elucidating the aetiology of diabetes. Diabetes Metab Res Rev (2011) 0.88
Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol Scand (1990) 0.88
Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol (2008) 0.88
Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J Lipid Res (2009) 0.87
CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One (2012) 0.87
Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest (2011) 0.87